ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 112
- Registration Number
- NCT06698926
- Locations
- 🇺🇸
Acpru /Id# 270532, Grayslake, Illinois, United States
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
- Conditions
- Bipolar I DisorderBipolar II Disorder
- Interventions
- Drug: Placebo for Icalcaprant
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 237
- Registration Number
- NCT06696755
Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participants After Multiple Migraine Attacks In Canada
- Conditions
- Migraine
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 167
- Registration Number
- NCT06692881
- Locations
- 🇨🇦
Genge Partners /ID# 273302, Montreal, Quebec, Canada
🇨🇦Diex Recherche Sherbrooke /ID# 271677, Sherbrooke, Quebec, Canada
🇨🇦Dr May Ong INC /ID# 271474, Vancouver, British Columbia, Canada
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
- Conditions
- Advanced High-Grade Epithelial OvarianPrimary PeritonealFallopian Tube CancersHigh Folate Receptor-Alpha ExpressionPlatinum Resistant
- Interventions
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 110
- Registration Number
- NCT06682988
A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 88
- Registration Number
- NCT06673238
- Locations
- 🇺🇸
Acpru /Id# 270279, Grayslake, Illinois, United States
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 165
- Registration Number
- NCT06667687
- Locations
- 🇺🇸
Carolina BioOncology Institute /ID# 265259, Huntersville, North Carolina, United States
🇺🇸Willamette Valley Cancer Institute and Research Center /ID# 270945, Eugene, Oregon, United States
🇺🇸Texas Oncology - Central/South Texas /ID# 270946, Austin, Texas, United States
Study To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa in Adult Participants With Advanced Parkinson Disease in Real Life Setting
- Conditions
- Advanced Parkinson Disease
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 200
- Registration Number
- NCT06639620
- Locations
- 🇫🇷
Centre Hospitalier Emile Durkheim - Site Plateau de la Justice /ID# 267183, Epinal CEDEX, Vosges, France
🇫🇷Centre Hospitalier Public du Cotentin - Hôpital Pasteur /ID# 265950, Cherbourg-en-Cotentin, France
🇫🇷Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou /ID# 267665, Rennes, France
A Study to Evaluate Adverse Events and How the Drug Moves Through the Body From Subcutaneous (SC) and Intravenous (IV) Doses of ABBV-382 in Healthy Adult Chinese Volunteers
- Conditions
- Healthy Volunteer
- Interventions
- Drug: Placebo for ABBV-382
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 24
- Registration Number
- NCT06632938
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital /ID# 264785, Shanghai, Shanghai, China
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
- Conditions
- Urothelial Carcinoma
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 150
- Registration Number
- NCT06632951
- Locations
- 🇺🇸
Highlands Oncology Group - Springdale /ID# 270290, Springdale, Arkansas, United States
🇺🇸University of California San Francisco - Mission Bay /ID# 270289, San Francisco, California, United States
🇺🇸Medical Oncology Hematology Consultants /ID# 271347, Newark, Delaware, United States
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
- Conditions
- Locally Advanced Unresectable or Metastatic Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaEsophageal Adenocarcinoma
- Interventions
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 180
- Registration Number
- NCT06628310
- Locations
- 🇺🇸
City of Hope National Medical Center /ID# 268690, Duarte, California, United States
🇺🇸City of Hope Orange County Lennar Foundation Cancer Center /ID# 272630, Irvine, California, United States
🇺🇸UCLA - Santa Monica /ID# 270024, Santa Monica, California, United States